Summary of COVID-19 crizanlizumab studies

1. Leucker et al., Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19

42 patient crizanlizumab late treatment RCT: 35% lower hospital discharge (p=0.16).
RCT 54 hospitalized COVID-19 patients showing crizanlizumab treatment reduced soluble P-selectin levels, increased D-dimer levels, and decreased prothrombin fragment 1.2 compared to placebo. There were no significant differences in inflammatory markers, clinical outcomes, or adverse events between groups. The authors hypothesize that crizanlizumab may induce endogenous thrombolysis in COVID-19.
Dec 2021, JACC: Basic to Translational Science, https://www.sciencedirect.com/science/article/pii/S2452302X21003156, https://c19p.org/leucker

2. Solomon et al., Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial

421 patient crizanlizumab late treatment RCT: 33% higher mortality (p=0.24) and 43% worse results (p=0.16).
RCT 422 hospitalized COVID-19 patients showing no significant difference in mortality or organ support-free days with crizanlizumab, a P-selectin inhibitor. There was a trend towards increased mortality with crizanlizumab. The study was stopped early for futility.
Aug 2023, Circulation, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065190, https://c19p.org/solomon